BR100 Decreased By (-0.15%)
BR30 Decreased By (-0.74%)
KSE100 Decreased By (-0.41%)
KSE30 Decreased By (-0.67%)
BECO 5.80 Decreased By ▼ -0.23 (-3.81%)
BML 58.03 Increased By ▲ 5.28 (10.01%)
BOP 33.85 Decreased By ▼ -0.40 (-1.17%)
CNERGY 8.15 Decreased By ▼ -0.01 (-0.12%)
DCL 11.77 Decreased By ▼ -0.57 (-4.62%)
FCCL 53.35 Decreased By ▼ -0.54 (-1%)
FCSC 5.40 Increased By ▲ 0.18 (3.45%)
FFL 17.89 Decreased By ▼ -0.14 (-0.78%)
FNEL 1.31 Increased By ▲ 0.01 (0.77%)
HUMNL 11.06 Increased By ▲ 0.06 (0.55%)
KEL 8.05 Decreased By ▼ -0.06 (-0.74%)
KOSM 5.45 Increased By ▲ 0.07 (1.3%)
MLCF 87.19 Decreased By ▼ -0.86 (-0.98%)
NBP 184.60 Decreased By ▼ -1.88 (-1.01%)
PACE 11.62 Increased By ▲ 0.90 (8.4%)
PAEL 40.31 Increased By ▲ 0.37 (0.93%)
PIAHCLA 26.10 Decreased By ▼ -0.07 (-0.27%)
PIBTL 17.09 Decreased By ▼ -0.23 (-1.33%)
PPL 228.40 Decreased By ▼ -4.38 (-1.88%)
PRL 34.59 Decreased By ▼ -0.36 (-1.03%)
PTC 67.35 Decreased By ▼ -0.21 (-0.31%)
SEARL 91.00 Increased By ▲ 0.07 (0.08%)
SSGC 26.90 Decreased By ▼ -0.27 (-0.99%)
TELE 8.53 Decreased By ▼ -0.04 (-0.47%)
THCCL 66.14 Increased By ▲ 6.01 (10%)
TPLP 9.29 Increased By ▲ 0.53 (6.05%)
TREET 24.59 Increased By ▲ 0.05 (0.2%)
TRG 71.69 Decreased By ▼ -0.06 (-0.08%)
WAVES 10.98 Increased By ▲ 1.00 (10.02%)
WTL 1.28 Increased By ▲ 0.02 (1.59%)
World

Germany's COVID-19 vaccination centres to hit capacity by end of March

  • Germany has so far been starved of shots as drugmakers faced production problems, but shortages are likely to ease as deliveries accelerate.
  • BioNTech's shot, made in partnership with US drug company Pfizer, was the first to win approval for use in the European Union.
Published February 10, 2021 Updated February 10, 2021 08:03pm
By

BERLIN: Germany will run up against limits on its capacity to inoculate people against COVID-19 by the end of March, health ministry documents showed, as an expected increase in supply puts its network of vaccination centres to the test.

Germany has so far been starved of shots as drugmakers faced production problems, but shortages are likely to ease as deliveries accelerate, according to a revised vaccine strategy released by the health ministry on Wednesday.

The strategy update came as German biotech startup BioNTech launched a new facility in the German town of Marburg, expecting first vaccines made there to be distributed in early April.

BioNTech's shot, made in partnership with US drug company Pfizer, was the first to win approval for use in the European Union.

Germany is also getting vaccines from Moderna and AstraZeneca. The Pfizer and Moderna shots need to be kept frozen, while Astra's can be stored in a fridge, making it suitable for administration by family doctors.

Around 2.4 million people have been vaccinated in Germany, or 2.9% of the population, since it started vaccinations in December, health ministry data showed.

Initial shortages should give way in the second quarter to more abundant supply, when Germany expects to receive 77 million vaccine doses. Chancellor Angela Merkel has promised shots to all adults who want one by the end of the summer.

To reach this target, vaccinations will be offered at general practitioners' clinics, working in parallel with the existing network of more than 400 vaccination centres, the plan document read.

"It is becoming clear that the vaccination centres will have to continue to operate for a longer period of time, even after doctors' practices are involved," it read.

In the plan, Germany's Institute for Statutory Health Care (Zi) recommended increasing the daily capacity of vaccination centres to 300,000 from 200,000 to meet targets.

According to Zi calculations and based on drugmakers' delivery commitments, Germany will be able to inoculate around three million people a week from May and administer around one million shots a day by the end of June.

Comments

Comments are closed for this article.